WebIn December 2013, the Company formed a subsidiary, Cytocom Inc. (“Cytocom”), to focus on conducting LDN and MENK clinical trials in the United States. The Company also transferred certain rights to Cytocom, including rights, titles, and interests in or relating to intellectual property, which are further described in the section of ... WebSep 28, 2024 · On June 24, 2024, Cytocom completed the acquisition of ImQuest Life Sciences, Inc. and its subsidiaries ("ImQuest") in accordance with the Agreement and Plan of Merger by and among Cytocom and ImQuest dated as of July 17, 2024, and gained control of ImQuest.

Current Report Filing (8-k) - Investors Hub

WebOn June 24, 2024, Cytocom completed the acquisition of ImQuest Life Sciences, Inc. and its subsidiaries (“ImQuest”) in accordance with the Agreement and Plan of Merger by … WebCytocom Subsidiary Inc. COUNTRY NAME: USA TICKER SYMBOL: STAB EXCHANGE NAME: NASDAQ - - Links on this page: Page Last Updated: 03/08/2024. Note: If you need help accessing information in different file formats, see ... h \u0026 j family holdings

Cytocom Announces Acquisition of ImQuest Life Sciences

WebCYTO-200 Noroxymorphone Platform. CYTO-200 program therapies, are noroxymorphone analogs developed by discovering the anti-angiogenic and anti-inflammatory properties of naltrexone, yielding a new way of fighting … WebJul 29, 2024 · Cytocom intends to draw down the first $15 million within 30 days of the closing of the recently completed merger between Cleveland BioLabs and Cytocom. A combination of debt and equity financing ... WebOct 21, 2024 · Cytocom, Inc. is a leader in immune modulation for the treatment of serious disease is a company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. h \u0026 i tv schedule today